Clinical Trial Update: Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating flavopiridol and vorinostat in relapsed or refractory acute leukemias and related myeloid disorders has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Anemia with Excess Blasts
• Chronic Myeloid Leukemia

Drugs mentioned

• Flavopiridol (alvocidib)
• Vorinostat (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Blastic Phase Chronic Myelogenous Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 | Status: COMPLETED